



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 99,371)

RECEIVED  
MAR 13 2001  
TECH CENTER 1600/2900

In re Application of: Thomason et al.

Serial No.: 09/391,861

Filed: September 7, 1999

For: Fibroblast Growth Factor-like  
Polypeptides

Before the Examiner:  
C. Stroup

Group Art Unit: 1633

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir/Madam:

**INFORMATION DISCLOSURE STATEMENT**

This statement is filed under 37 C.F.R. §§1.97-1.98 in compliance with the duty of disclosure set forth in 37 C.F.R. §1.56 and fee pursuant to 37 C.F.R. §§1.97(c) and 1.17(p).

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form. Copies of the listed documents are enclosed.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the claimed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

A check including \$240.00 to cover the submission of an Information Disclosure Statement under 37 C.F.R. §1.97(c) is attached. The Commissioner is authorized to charge any deficiency or credit any excess in this fee to Deposit Account No. 00000001 132490 09391861

01 FC:126

180.00 CH

Respectfully submitted,  
McDonnell Boehnen Hulbert & Berghoff

Dated: March 7, 2001

By: 

Kevin E. Noonan, Ph.D.

Reg. No. 35,303